CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper



March 10, 2021

In this installment of Teach Me in 10, we're joined by Matt Cooper, co-founder and chief scientific officer at Wugen, Inc. He is also assistant professor of medicine at Washington University. Matt discusses what T cells are and how they can be engineered to recognize cancer cells. This can be achieved by incorporating a specific receptor – the chimeric antigen receptor (CAR) – which results in the generation of CAR T cells. “CAR T cells are essentially a living targeted drug,” says Matt. Learn more about the key challenges related to engineering CAR T cells, discover ways to enable the broader application of these cells and hear about the development of allogeneic CAR T cells as an “off-the-shelf” treatment for cancer. You can learn more about CAR T cells by checking out the following content: Treating Cancer – 5 Types of Immunotherapy, Opinionated Science Episode 14: Cancer Immunotherapy: Vaccines, Viruses and Nobel Prizes and Cancer and the Immune System.

Cancer ResearchCell ScienceDrug DiscoveryImmunology

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.